BioNTech SE

General information
BioNTech SE
An der Goldgrube 12
55131 Mainz, Rhineland-Palatinate
Germany

Contact person: Constanze Blume, Senior Vice President Global Regulatory Affairs
Company main phone: +49 (6131) 90840
Company main fax:  +49 (6131) 90842121
Website:  https://biontech.de
Year founded:2008
Source of foundation:Spin-off from university
Name of foundation source:Johannes Gutenberg University Mainz
No. of employees: Worldwide:  6133
Corporate description / mission:
BioNTech SE is a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company has several manufacturing sites capable of developing fully automated production processes for on-demand production of therapies and vaccines. The company's product BNT111 is an mRNA cancer vaccine candidate encoding a fixed set of four melanoma-associated antigens aiming to trigger a strong and precise immune response in patients with advanced melanoma.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2019
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Antibody-drug-conjugate
  • Cell therapy
  • Immunotherapy
  • Nucleic acid drugs
  • Small molecules
  • Vaccines
Primary therapeutic areas:
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
Business model:
  • Manufacturer
  • Service company
  • Supplier / Distributor
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:7
Phase I:19
Phase II:26
Phase III:7
On the market:3
Description of products:
BNT111
BNT113
BNT116, etc.
Technology used:
mRNA-based Platforms
Protein-based Platforms
Cell Therapy-based Platforms
Small Molecule-based Platforms
Financing details
Market cap. / valuation:USD 28'725.65M
Collaborations & Clients
Partnering strategy / collaborations:
Autolus Therapeutics
Bill & Melinda Gates Foundation
Biotheus
Coalition for Epidemic Preparedness Innovations (CEPI)
Crescendo Biologics
Duality Biologics
Fosun Pharma, etc.
X